Stocktoria
CATALYST PHARMACEUTICALS, INC. CPRX
CATALYST PHARMACEUTICALS, INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $589.0M | $491.7M | $398.2M | $214.2M | $140.8M | $119.1M | $102.3M | $500,000 | $0 | $0 |
| R&D expense | $12.7M | $12.6M | $93.2M | $19.8M | $16.9M | $16.5M | $18.8M | $19.9M | $11.4M | $11.4M |
| SG&A expense | $193.8M | $177.7M | $133.7M | $57.1M | $49.6M | $44.2M | $36.9M | $15.9M | — | — |
| Operating income | $257.8M | $195.1M | $86.8M | $101.8M | $52.4M | $41.3M | $31.8M | -$35.3M | -$18.7M | -$19.3M |
| Income tax | $69.2M | $52.4M | $23.1M | $21.6M | $13.2M | -$33.1M | $1.5M | $0 | $0 | $0 |
| Net income | $214.3M | $163.9M | $71.4M | $83.1M | $39.5M | $75.0M | $31.9M | -$34.0M | -$18.4M | -$18.1M |
| EPS (diluted) | $1.68 | $1.31 | $0.63 | $0.75 | $0.37 | $0.71 | $0.30 | $-0.33 | — | — |
| Operating cash flow | $208.7M | $239.8M | $143.6M | $116.0M | $60.4M | $45.0M | $34.6M | -$26.1M | -$13.7M | -$18.0M |
| Free cash flow | $208.6M | $239.3M | $143.4M | $116.0M | $59.4M | $45.0M | $34.6M | -$26.2M | — | -$18.1M |
| Cash & equivalents | $709.2M | $517.6M | $137.6M | $298.4M | $171.4M | $130.2M | $89.5M | $16.6M | $57.5M | $13.9M |
| Inventory | $37.2M | $19.5M | $15.6M | $6.8M | $7.9M | $4.7M | $2.0M | $56,012 | $0 | — |
| Total assets | $1.1B | $851.4M | $470.1M | $375.6M | $237.8M | $192.4M | $112.4M | $60.4M | $85.4M | $41.7M |
| Total liabilities | $149.7M | $123.8M | $82.2M | $75.2M | $31.0M | $22.8M | $24.7M | $9.7M | $4.4M | $2.4M |
| Shareholders' equity | $954.3M | $727.6M | $387.9M | $300.4M | $206.8M | $169.6M | $87.6M | $50.8M | $81.0M | $39.3M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +19.8% | +23.5% | +85.9% | +52.1% | +18.3% | +16.4% | +20361.3% | — | — | — |
| Net income growth | +30.8% | +129.5% | -14.0% | +110.4% | -47.3% | +135.2% | — | — | — | — |
| EPS growth | +28.2% | +107.9% | -16.0% | +102.7% | -47.9% | +136.7% | — | — | — | — |
| Free cash flow growth | -12.8% | +66.9% | +23.6% | +95.5% | +31.8% | +30.2% | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.